WO2000061164A1 - Modulation de la fonction d'un tissu excitable par administration peripherique d'une erythropoietine - Google Patents

Modulation de la fonction d'un tissu excitable par administration peripherique d'une erythropoietine Download PDF

Info

Publication number
WO2000061164A1
WO2000061164A1 PCT/US2000/010019 US0010019W WO0061164A1 WO 2000061164 A1 WO2000061164 A1 WO 2000061164A1 US 0010019 W US0010019 W US 0010019W WO 0061164 A1 WO0061164 A1 WO 0061164A1
Authority
WO
WIPO (PCT)
Prior art keywords
epo
erythropoietin
tissue
molecule
receptor
Prior art date
Application number
PCT/US2000/010019
Other languages
English (en)
Inventor
Michael Brines
Anthony Cerami
Carla Cerami
Original Assignee
Kenneth S. Warren Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002383940A priority Critical patent/CA2383940A1/fr
Priority to MXPA01010177A priority patent/MXPA01010177A/es
Application filed by Kenneth S. Warren Laboratories filed Critical Kenneth S. Warren Laboratories
Priority to PL00352223A priority patent/PL352223A1/xx
Priority to JP2000610496A priority patent/JP2003520194A/ja
Priority to SK1441-2001A priority patent/SK14412001A3/sk
Priority to EP00923344A priority patent/EP1171147A4/fr
Priority to IL14589500A priority patent/IL145895A0/xx
Priority to AU43487/00A priority patent/AU784550B2/en
Priority to NZ514690A priority patent/NZ514690A/en
Priority to BR0009737-3A priority patent/BR0009737A/pt
Priority to EA200101073A priority patent/EA004766B1/ru
Priority to CN008087466A priority patent/CN1607957B/zh
Publication of WO2000061164A1 publication Critical patent/WO2000061164A1/fr
Priority to IL145895A priority patent/IL145895A/en
Priority to IS6104A priority patent/IS6104A/is
Priority to NO20014991A priority patent/NO20014991L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés et des compositions permettant de protéger et d'améliorer la fonction de tissus excitables chez les mammifères par administration systémique d'un modulateur de l'activité du récepteur de l'érythropoïétine, notamment l'érythropoïétine, par le biais de signaux via un récepteur activé par EPO pour moduler la fonction de tissus excitables. Ces tissus excitables sont formés de tissus neuronaux centraux, notamment du cerveau, de tissus neuronaux périphériques et de tissus de la rétine et du coeur. Grâce à la protection de ces tissus, on peut traiter l'hypoxie, les troubles épileptiques, les maladies neurodégénératives, l'hypoglycémie et l'empoisonnement neurotoxique. L'amélioration de la fonction des tissus excitables contribue à faciliter l'apprentissage et développer la mémoire. L'invention concerne également des compositions et des procédés tendant à faciliter le transport de molécules à travers les barrières de la zone de déplétion de cellules endothéliales, notamment la barrière hémato-encéphalique par l'association de molécules avec un modulateur de l'activité du récepteur de l'érythropoïétine, notamment une érythropoïétine.
PCT/US2000/010019 1999-04-13 2000-04-13 Modulation de la fonction d'un tissu excitable par administration peripherique d'une erythropoietine WO2000061164A1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
NZ514690A NZ514690A (en) 1999-04-13 2000-04-13 Modulation of excitable tissue function by peripherally administered erythropoietin
AU43487/00A AU784550B2 (en) 1999-04-13 2000-04-13 Modulation of excitable tissue function by peripherally administered erythropoietin
PL00352223A PL352223A1 (en) 1999-04-13 2000-04-13 Modulation of excitable tissue function by peripherally administered erythropoietin
MXPA01010177A MXPA01010177A (es) 1999-04-13 2000-04-13 Modulacion de la funcion del tejido excitable mediante eritropoyetina administrada en forma periferica.
SK1441-2001A SK14412001A3 (sk) 1999-04-13 2000-04-13 Farmaceutický prostriedok, farmaceutický kit s jeho obsahom a jeho použitie
EP00923344A EP1171147A4 (fr) 1999-04-13 2000-04-13 Modulation de la fonction d'un tissu excitable par administration peripherique d'une erythropoietine
BR0009737-3A BR0009737A (pt) 1999-04-13 2000-04-13 Composição farmacêutica, kit farmacêutico com um ou mais recipientes, métodos para a proteção de um mamìfero de uma patologia resultante de lesão de tecido excitável, para a intensificação da função de um tecido excitável normal ou anormal em um mamìfero, e para a facilitação da transcitose de uma molécula através de uma barreira celular endotelial em um mamìfero, e, composição para transporte de uma molécula via transcinose através de uma barreira celular endotelial
CA002383940A CA2383940A1 (fr) 1999-04-13 2000-04-13 Modulation de la fonction d'un tissu excitable par administration peripherique d'une erythropoietine
JP2000610496A JP2003520194A (ja) 1999-04-13 2000-04-13 末梢投与したエリスロポエチンによる興奮組織機能のモジュレート
IL14589500A IL145895A0 (en) 1999-04-13 2000-04-13 Modulation of excitable tissue function by peripherally administered erythropoietin
EA200101073A EA004766B1 (ru) 1999-04-13 2000-04-13 Модуляция функции возбуждаемых тканей за счет периферического введения эритропоэтина
CN008087466A CN1607957B (zh) 1999-04-13 2000-04-13 外周给药的红细胞生成素对应激组织功能的调制
IL145895A IL145895A (en) 1999-04-13 2001-10-11 Modulation of excitable tissue function by peripherally administered erythropoietin
IS6104A IS6104A (is) 1999-04-13 2001-10-11 Stilling á örvanlegum vef með því að bera erýþrópóetín á útvortis
NO20014991A NO20014991L (no) 1999-04-13 2001-10-12 Modulering av eksiterbar vevsfunksjon ved perifert administrert erytropoietin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29093899A 1999-04-13 1999-04-13
US09/290,938 1999-04-13
US54722000A 2000-04-11 2000-04-11
US09/547,220 2000-04-11

Publications (1)

Publication Number Publication Date
WO2000061164A1 true WO2000061164A1 (fr) 2000-10-19

Family

ID=26966493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010019 WO2000061164A1 (fr) 1999-04-13 2000-04-13 Modulation de la fonction d'un tissu excitable par administration peripherique d'une erythropoietine

Country Status (21)

Country Link
EP (1) EP1171147A4 (fr)
JP (1) JP2003520194A (fr)
KR (2) KR100883232B1 (fr)
CN (1) CN1607957B (fr)
AU (1) AU784550B2 (fr)
BG (1) BG65353B1 (fr)
BR (1) BR0009737A (fr)
CA (1) CA2383940A1 (fr)
CR (1) CR6501A (fr)
CZ (1) CZ20013695A3 (fr)
EA (1) EA004766B1 (fr)
HU (1) HUP0201598A3 (fr)
IL (2) IL145895A0 (fr)
IS (1) IS6104A (fr)
MX (1) MXPA01010177A (fr)
NO (1) NO20014991L (fr)
NZ (4) NZ533098A (fr)
PL (1) PL352223A1 (fr)
SK (1) SK14412001A3 (fr)
TR (2) TR200402194T2 (fr)
WO (1) WO2000061164A1 (fr)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002135A1 (fr) 2000-06-30 2002-01-10 Tokyo Metropolitan Institute Of Gerontology Preventifs et remedes contre des maladies associees a la demyelinisation
WO2002020031A2 (fr) * 2000-09-04 2002-03-14 Hannelore Ehrenreich Procede de traitement de la schizophrenie et des psychoses apparentees, et utilisation de l'erythropoietine ou des derives de l'erythropoietine pour le traitement des schizophrenies et psychoses apparentees
WO2002064085A2 (fr) * 2001-02-02 2002-08-22 Ortho-Mcneil Pharmaceutical, Inc. Traitement de dysfonctionnements neurologiques au moyen de sulfamates de fructopyranose et d'erythropoietine
WO2003020161A2 (fr) * 2001-12-07 2003-03-13 Applied Vaccine Technologies Corp. Dispositif de modulation de reponse immunitaire chez l'animal
WO2003057242A1 (fr) * 2002-01-09 2003-07-17 Crucell Holland B.V. Utilisation de l'erythropoietine pour le traitement preventif ou curatif de l'insuffisance cardiaque
WO2003089468A1 (fr) * 2002-04-19 2003-10-30 Crucell Holland B.V. Methodes et moyens de production de proteines avec des modifications post-traductionnelles preetablies
WO2003097106A2 (fr) * 2002-05-21 2003-11-27 The Queen's University Of Belfast Medicaments
WO2004012759A2 (fr) * 2002-07-26 2004-02-12 Epoplus Gmbh & Co. Kg Utilisation de l'erythropoietine
EP1552298A2 (fr) * 2002-07-01 2005-07-13 The Kenneth S. Warren Institute, Inc. Cytokines protectrices des tissus recombinees et acides nucleiques codants associes pour la protection, la restauration et l'amelioration de cellules, de tissus et d'organes sensibles
DE102004004509A1 (de) * 2004-01-23 2005-08-18 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
EP1622570A2 (fr) * 2003-04-25 2006-02-08 The Kenneth S. Warren Institute, Inc. Complexe du recepteur de cytokine protecteur de tissus, dosages permettant d'identifier des composes protecteurs de tissus et utilisations associees
EP1633383A2 (fr) * 2003-03-27 2006-03-15 Janssen Pharmaceutica N.V. Utilisation de l'erythropoietine pour un retablissement a la suite d'un accident ischemique cerebral
US7132280B2 (en) 1999-04-15 2006-11-07 Crucell Holland, B.V. Recombinant protein production in a human cell
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
WO2007039436A1 (fr) * 2005-09-28 2007-04-12 F. Hoffmann-La Roche Ag Traitement des maladies neurodégénératives
WO2007068983A1 (fr) * 2005-12-15 2007-06-21 Isis Innovation Ltd Nouveau traitement
US7291484B2 (en) 2003-05-09 2007-11-06 Crucell Holland B.V. Processes for culturing E1-immortalized cells to increase product yields
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
WO2009010107A1 (fr) * 2007-07-19 2009-01-22 Hannelore Ehrenreich Utilisation d'activation ou de stimulation du récepteur de l'epo pour l'amélioration du score edss dans des patients présentant une sclérose en plaques
US7504248B2 (en) 2001-12-07 2009-03-17 Crucell Holland B.V. Production of viruses viral isolates and vaccines
EP2037952A1 (fr) * 2006-04-29 2009-03-25 Shanghai Institutes for Biological sciences, Chinese Academy of Sciences Administration d'érythropoïétine par injection dans le vitré
US7514072B1 (en) 1998-12-14 2009-04-07 Hannelore Ehrenreich Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
EP2101808A2 (fr) * 2007-01-10 2009-09-23 Edison Pharmaceuticals, Inc. Traitement de troubles de la chaîne respiratoire, utilisant des composés qui présentent une activité érythropoïétine ou thrombopoïétine
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7790675B2 (en) 2004-11-09 2010-09-07 Medizinische Universitaet Wien Method for increasing frataxin expression
EP2292770A2 (fr) 2001-10-29 2011-03-09 Crucell Holland B.V. Procédés et moyen pour la production de protéines avec des modifications prédéterminées après translation
EP2319530A1 (fr) 2006-01-27 2011-05-11 Hannelore Ehrenreich Procédé de traitement et/ou de prophylaxie de la sclérose multiple, et utilisation d'érythropoiétine pour la fabrication d'un médicament destiné au traitement intermittent et/ou à la prophylaxie intermittente de la sclérose multiple
EP2349454A1 (fr) * 2008-11-07 2011-08-03 Rosalind Franklin University of Medicine and Science Facilitation de la réanimation en cas d'arrêt cardiaque à l'aide de l'érythropoïétine
US8071554B2 (en) 2005-08-05 2011-12-06 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
US20120142589A1 (en) * 2000-12-29 2012-06-07 The Kenneth S. Warren Institute, Inc. Tissue-protective cytokines for the protection, restoration and enhancement of responsive cells, tissues and organs
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
EP2281828A3 (fr) * 2000-12-29 2012-10-24 The Kenneth S. Warren Institute, Inc. Compositions comprenant de l'érythropoiétine modifiée
US8853358B2 (en) 2008-01-22 2014-10-07 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2519695C2 (ru) * 2010-07-21 2014-06-20 Олег Ильич Эпштейн Лекарственное средство для лечения синдрома дефицита внимания и способ лечения синдрома дефицита внимания
CN111066727B (zh) * 2019-12-20 2021-08-27 中国人民解放军陆军军医大学 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806524A (en) * 1984-10-18 1989-02-21 Chugai Seiyaku Kabushiki Kaisha Stable erythropoietin preparation and process for formulating the same
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
DE19857609A1 (de) * 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806524A (en) * 1984-10-18 1989-02-21 Chugai Seiyaku Kabushiki Kaisha Stable erythropoietin preparation and process for formulating the same
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRIMM G. ET AL.: "Improvement of brain function in hemodialysis patients treated with erythropoietin", KIDNEY INTERNATIONAL, vol. 38, 1990, pages 480 - 486, XP002930886 *
NISSENSON A.R. ET AL.: "Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy and nervous system effects", ANNALS OF INTERNAL MEDICINE, vol. 114, no. 5, 1 March 1991 (1991-03-01), pages 402 - 416, XP002930887 *
See also references of EP1171147A4 *

Cited By (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514072B1 (en) 1998-12-14 2009-04-07 Hannelore Ehrenreich Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
US7833753B2 (en) 1999-04-15 2010-11-16 Crucell Holland B.V. Methods of producing erythropoietin isoforms comprising Lewis-X structures and high sialic acid content and compositions of the same
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US7132280B2 (en) 1999-04-15 2006-11-07 Crucell Holland, B.V. Recombinant protein production in a human cell
US7470523B2 (en) 1999-04-15 2008-12-30 Crucell Holland B.V. Recombinant protein production in a human cell
US7491532B2 (en) 1999-04-15 2009-02-17 Crucell Holland, B.V. Recombinant protein production in a human cell
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7833788B2 (en) 1999-11-26 2010-11-16 Crucell Holland B.V. Production of vaccines
US7964198B2 (en) 1999-11-26 2011-06-21 Crucell Holland B.V. Production of vaccines
US7550284B2 (en) 1999-11-26 2009-06-23 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US8039253B2 (en) 2000-06-30 2011-10-18 Tokyo Metropolitan Institute Of Gerontology Pharmaceutical for prevention and treatment of demyelinating disease
WO2002002135A1 (fr) 2000-06-30 2002-01-10 Tokyo Metropolitan Institute Of Gerontology Preventifs et remedes contre des maladies associees a la demyelinisation
WO2002020031A3 (fr) * 2000-09-04 2002-08-01 Hannelore Ehrenreich Procede de traitement de la schizophrenie et des psychoses apparentees, et utilisation de l'erythropoietine ou des derives de l'erythropoietine pour le traitement des schizophrenies et psychoses apparentees
WO2002020031A2 (fr) * 2000-09-04 2002-03-14 Hannelore Ehrenreich Procede de traitement de la schizophrenie et des psychoses apparentees, et utilisation de l'erythropoietine ou des derives de l'erythropoietine pour le traitement des schizophrenies et psychoses apparentees
US20120142589A1 (en) * 2000-12-29 2012-06-07 The Kenneth S. Warren Institute, Inc. Tissue-protective cytokines for the protection, restoration and enhancement of responsive cells, tissues and organs
JP2015221816A (ja) * 2000-12-29 2015-12-10 ザ ケネス エス．ウォーレン インスティテュート，インコーポレーテッド エリスロポエチン応答性細胞、組織及び器官の保護、回復ならびに増強
JP2013166775A (ja) * 2000-12-29 2013-08-29 Kenneth S Warren Inst Inc エリスロポエチン応答性細胞、組織及び器官の保護、回復ならびに増強
EP2281828A3 (fr) * 2000-12-29 2012-10-24 The Kenneth S. Warren Institute, Inc. Compositions comprenant de l'érythropoiétine modifiée
KR100896971B1 (ko) * 2001-02-02 2009-05-14 오르토-맥네일 파마슈티칼, 인코퍼레이티드 프락토피라노오스 설파메이트 및 에리트로포이에틴을포함하는 신경계 기능장애 치료법
US6908902B2 (en) * 2001-02-02 2005-06-21 Ortho-Mcneil Pharmaceutical, Inc. Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
WO2002064085A2 (fr) * 2001-02-02 2002-08-22 Ortho-Mcneil Pharmaceutical, Inc. Traitement de dysfonctionnements neurologiques au moyen de sulfamates de fructopyranose et d'erythropoietine
EP1471871A2 (fr) * 2001-02-02 2004-11-03 Ortho-McNeil Pharmaceutical, Inc. Traitement de dysfonctionnements neurologiques au moyen de sulfamates de fructopyranose et d'erythropoietine
EP1471871A4 (fr) * 2001-02-02 2005-11-09 Ortho Mcneil Pharm Inc Traitement de dysfonctionnements neurologiques au moyen de sulfamates de fructopyranose et d'erythropoietine
WO2002064085A3 (fr) * 2001-02-02 2004-09-10 Ortho Mcneil Pharm Inc Traitement de dysfonctionnements neurologiques au moyen de sulfamates de fructopyranose et d'erythropoietine
EP2292770A2 (fr) 2001-10-29 2011-03-09 Crucell Holland B.V. Procédés et moyen pour la production de protéines avec des modifications prédéterminées après translation
WO2003020161A3 (fr) * 2001-12-07 2003-06-05 Applied Vaccine Technologies C Dispositif de modulation de reponse immunitaire chez l'animal
WO2003020161A2 (fr) * 2001-12-07 2003-03-13 Applied Vaccine Technologies Corp. Dispositif de modulation de reponse immunitaire chez l'animal
US8802417B2 (en) 2001-12-07 2014-08-12 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US7504248B2 (en) 2001-12-07 2009-03-17 Crucell Holland B.V. Production of viruses viral isolates and vaccines
US7335490B2 (en) 2002-01-09 2008-02-26 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
WO2003057242A1 (fr) * 2002-01-09 2003-07-17 Crucell Holland B.V. Utilisation de l'erythropoietine pour le traitement preventif ou curatif de l'insuffisance cardiaque
WO2003089468A1 (fr) * 2002-04-19 2003-10-30 Crucell Holland B.V. Methodes et moyens de production de proteines avec des modifications post-traductionnelles preetablies
WO2003097106A3 (fr) * 2002-05-21 2004-02-12 Univ Belfast Medicaments
US7344699B2 (en) 2002-05-21 2008-03-18 The Queen's University Of Belfast Drug conjugate comprising an erythropoietin receptor ligand and an anticancer agent
WO2003097106A2 (fr) * 2002-05-21 2003-11-27 The Queen's University Of Belfast Medicaments
EP1552298A4 (fr) * 2002-07-01 2006-11-08 Kenneth S Warren Inst Inc Cytokines protectrices des tissus recombinees et acides nucleiques codants associes pour la protection, la restauration et l'amelioration de cellules, de tissus et d'organes sensibles
EP1552298A2 (fr) * 2002-07-01 2005-07-13 The Kenneth S. Warren Institute, Inc. Cytokines protectrices des tissus recombinees et acides nucleiques codants associes pour la protection, la restauration et l'amelioration de cellules, de tissus et d'organes sensibles
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US7745387B2 (en) 2002-07-26 2010-06-29 Epoplus Gmbh & Co. Kg Use of erythropoietin
WO2004012759A2 (fr) * 2002-07-26 2004-02-12 Epoplus Gmbh & Co. Kg Utilisation de l'erythropoietine
EA013966B1 (ru) * 2002-07-26 2010-08-30 Эпоплус Гмбх Унд Ко. Кг Применение эритропоэтина для лечения сахарного диабета
EP1779862A1 (fr) * 2002-07-26 2007-05-02 EPOPLUS GmbH & Co. KG Erythropoietine pour la stimulation des cellules progenitrices endotheliales
WO2004012759A3 (fr) * 2002-07-26 2004-06-03 Ferdinand Hermann Bahlmann Utilisation de l'erythropoietine
EP2191838A1 (fr) * 2002-07-26 2010-06-02 EPOPLUS GmbH & Co. KG Erythropoetine pour la stimulation des cellules precurseurs endotheliales
EA009463B1 (ru) * 2002-07-26 2007-12-28 Эпоплус Гмбх Унд Ко. Кг Применение эритропоэтина
US7396913B2 (en) 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
EP1633383A4 (fr) * 2003-03-27 2008-05-21 Janssen Pharmaceutica Nv Utilisation de l'erythropoietine pour un retablissement a la suite d'un accident ischemique cerebral
EP1633383A2 (fr) * 2003-03-27 2006-03-15 Janssen Pharmaceutica N.V. Utilisation de l'erythropoietine pour un retablissement a la suite d'un accident ischemique cerebral
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
EP1622570A2 (fr) * 2003-04-25 2006-02-08 The Kenneth S. Warren Institute, Inc. Complexe du recepteur de cytokine protecteur de tissus, dosages permettant d'identifier des composes protecteurs de tissus et utilisations associees
EP1622570A4 (fr) * 2003-04-25 2009-07-08 Kenneth S Warren Inst Inc Complexe du recepteur de cytokine protecteur de tissus, dosages permettant d'identifier des composes protecteurs de tissus et utilisations associees
US7608431B2 (en) 2003-05-09 2009-10-27 Crucell Holland B.V. Fed-batch process for production of erythropoietin in human embryonic retina cells that express adenovirus E1A
US8008043B2 (en) 2003-05-09 2011-08-30 Crucell Holland B.V. Cultures of E1-immortalized cells and processes for culturing the same to increase product yields therefrom
US7291484B2 (en) 2003-05-09 2007-11-06 Crucell Holland B.V. Processes for culturing E1-immortalized cells to increase product yields
DE102004004509A1 (de) * 2004-01-23 2005-08-18 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US7790675B2 (en) 2004-11-09 2010-09-07 Medizinische Universitaet Wien Method for increasing frataxin expression
EP2402450A1 (fr) 2004-12-30 2012-01-04 Crucell Holland B.V. Procédés pour obtenir des protéines recombinantes dotées d'une structure LacdiNac diminuée
US10100096B2 (en) 2005-08-05 2018-10-16 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
US9340598B2 (en) 2005-08-05 2016-05-17 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
US8071554B2 (en) 2005-08-05 2011-12-06 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
US8673861B2 (en) 2005-08-05 2014-03-18 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
US8716245B2 (en) 2005-08-05 2014-05-06 Araim Pharmaceuticals, Inc. Tissue protective peptides and uses thereof
CN101277715B (zh) * 2005-09-28 2013-03-27 弗·哈夫曼-拉罗切有限公司 神经变性疾病的治疗
AU2006298826B2 (en) * 2005-09-28 2010-04-01 F. Hoffmann-La Roche Ag Treatment of neurodegenerative disorders
WO2007039436A1 (fr) * 2005-09-28 2007-04-12 F. Hoffmann-La Roche Ag Traitement des maladies neurodégénératives
RU2467761C2 (ru) * 2005-09-28 2012-11-27 Ф.Хоффманн-Ля Рош Аг Лечение нейродегенеративных расстройств
TWI380824B (zh) * 2005-09-28 2013-01-01 Hoffmann La Roche 包含促紅血球形成分子之藥物及套組及其用途
WO2007068983A1 (fr) * 2005-12-15 2007-06-21 Isis Innovation Ltd Nouveau traitement
US9254312B2 (en) 2006-01-27 2016-02-09 Hannelore Ehrenreich Method for the treatment and/or prophylaxis of multiple sclerosis, and use of erythropoietin for the manufacture of a medicament for the intermittent treatment and/or intermittent prophylaxis of multiple sclerosis
EP2319530A1 (fr) 2006-01-27 2011-05-11 Hannelore Ehrenreich Procédé de traitement et/ou de prophylaxie de la sclérose multiple, et utilisation d'érythropoiétine pour la fabrication d'un médicament destiné au traitement intermittent et/ou à la prophylaxie intermittente de la sclérose multiple
AU2007247679B2 (en) * 2006-04-29 2012-12-06 Philadelphia Health And Education Corporation D/B/A Drexel University College Of Medicine Vitreous administration of erythropoietin
EP2037952A1 (fr) * 2006-04-29 2009-03-25 Shanghai Institutes for Biological sciences, Chinese Academy of Sciences Administration d'érythropoïétine par injection dans le vitré
EP2037952B1 (fr) * 2006-04-29 2015-10-21 Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences Administration d'érythropoïétine par injection dans le vitré
EP2101808A2 (fr) * 2007-01-10 2009-09-23 Edison Pharmaceuticals, Inc. Traitement de troubles de la chaîne respiratoire, utilisant des composés qui présentent une activité érythropoïétine ou thrombopoïétine
EP2101808A4 (fr) * 2007-01-10 2011-11-30 Edison Pharmaceuticals Inc Traitement de troubles de la chaîne respiratoire, utilisant des composés qui présentent une activité érythropoïétine ou thrombopoïétine
WO2009010107A1 (fr) * 2007-07-19 2009-01-22 Hannelore Ehrenreich Utilisation d'activation ou de stimulation du récepteur de l'epo pour l'amélioration du score edss dans des patients présentant une sclérose en plaques
US9180165B2 (en) 2007-07-19 2015-11-10 Hannelore Ehrenreich Use of EPO receptor activation or stimulation for the improvement of the EDSS score in patients with multiple sclerosis
US8853358B2 (en) 2008-01-22 2014-10-07 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US9580465B2 (en) 2008-01-22 2017-02-28 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
EP2349454A4 (fr) * 2008-11-07 2012-12-05 Univ Rosalind Franklin Medicine & Science Facilitation de la réanimation en cas d'arrêt cardiaque à l'aide de l'érythropoïétine
EP2349454A1 (fr) * 2008-11-07 2011-08-03 Rosalind Franklin University of Medicine and Science Facilitation de la réanimation en cas d'arrêt cardiaque à l'aide de l'érythropoïétine

Also Published As

Publication number Publication date
IS6104A (is) 2001-10-11
BR0009737A (pt) 2003-01-14
HUP0201598A2 (en) 2002-09-28
AU4348700A (en) 2000-11-14
NO20014991L (no) 2001-11-15
IL145895A0 (en) 2002-07-25
NZ533098A (en) 2006-04-28
NZ545478A (en) 2008-04-30
EA200101073A1 (ru) 2002-10-31
KR101012932B1 (ko) 2011-02-08
CN1607957A (zh) 2005-04-20
NZ560696A (en) 2010-03-26
KR100883232B1 (ko) 2009-02-10
AU784550B2 (en) 2006-05-04
PL352223A1 (en) 2003-08-11
EP1171147A4 (fr) 2003-05-14
NO20014991D0 (no) 2001-10-12
NZ514690A (en) 2004-07-30
SK14412001A3 (sk) 2002-03-05
BG65353B1 (bg) 2008-03-31
KR20070094997A (ko) 2007-09-27
MXPA01010177A (es) 2004-09-10
BG106058A (en) 2002-12-29
TR200402194T2 (tr) 2004-10-21
CR6501A (es) 2004-04-15
CZ20013695A3 (cs) 2002-02-13
JP2003520194A (ja) 2003-07-02
CN1607957B (zh) 2012-10-10
IL145895A (en) 2010-05-31
EP1171147A1 (fr) 2002-01-16
HUP0201598A3 (en) 2002-10-28
EA004766B1 (ru) 2004-08-26
KR20020000874A (ko) 2002-01-05
CA2383940A1 (fr) 2000-10-19
TR200103785T2 (tr) 2002-06-21

Similar Documents

Publication Publication Date Title
US7410941B1 (en) Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
AU784550B2 (en) Modulation of excitable tissue function by peripherally administered erythropoietin
US20080014193A1 (en) Modulation of excitable tissue function by peripherally administered erythropoietin
US7767643B2 (en) Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
AU2002239665B2 (en) Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
AU2002239665A1 (en) Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
AU2006200973A1 (en) Modulation of excitable tissue function by peripherally administered erythropoietin
WO2005084364A2 (fr) Cytokines de protection tissulaire a action prolongee pour la protection, la restauration, et l'amelioration de cellules, tissus et organes sensibles
UA89468C2 (uk) Модуляція функції тканин, що збуджуються за рахунок периферійного введення еритропоетину
AU2007200697A1 (en) Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00808746.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/010177

Country of ref document: MX

Ref document number: 514690

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 14412001

Country of ref document: SK

Ref document number: 43487/00

Country of ref document: AU

Ref document number: 2383940

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV2001-3695

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020017013093

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 610496

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 106058

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/01488/CH

Country of ref document: IN

Ref document number: 1488/CHE/2001

Country of ref document: IN

Ref document number: IN/PCT/2001/1488/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2000923344

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200101073

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2001/03785

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1020017013093

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000923344

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2001-3695

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2004/02194

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PV2005-116

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 43487/00

Country of ref document: AU